CD28 and neoplasm: To test whether the concentration of galectin-3 released by the freshly isolated tumor cells was not sufficient to inhibit Vδ1 T-cell proliferation, we added different concentrations of galectin-3 to PBMC either stimulated with zoledronate or anti-TCR Vδ1/anti-CD28 mAbs as illustrated in Figures 6C, D.